Eloise McLennan on Muck Rack

Eloise McLennan

Verified
Milton Keynes
As seen in: Deep Dive, Pharmaphorum, Yahoo Finance, Verdict, Railway Technology, Naval Technology, Airforce Technology, Army Technology, Pharmaceutical-Technology.com, Medical Device Network, Packaging Gateway
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Eloise

Contact Eloise, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dr Craig Primack: How telehealth closes obesity care gaps

|
By Eloise McLennan Verified
| Pharmaphorum Verified
Earlier this year, when US telehealth giant Hims & Hers first unveiled plans to acquire its Australian rival Eucalyptus for a whopping $1.15 billion, the company made a bold statement of intent to become the largest global player in the telehealth space. Through the deal, Hims & Hers would inherit a strong market presence in Australia, as well as access to several consumer brands; most notably the weight loss platform, Juniper, which operates in the UK, Germany, and Japan.
Open in Who Shared Issue with article?

Clinical Trials Round-Up: March and April 2026

|
By Eloise McLennan Verified
| Pharmaphorum Verified
Welcome to the second edition of the pharmaphorum Clinical Trials Round-Up for 2026. March and April offered no shortage of talking points for the clinical trials community. Promising oncology data, mixed results in immunology, and fresh evidence in metabolic disease all competed for attention.
Open in Who Shared Issue with article?

From data to deployment: Navigating AI adoption in pharma with Veeva

|
By Eloise McLennan Verified
| Pharmaphorum Verified
It’s safe to say that AI has firmly captured the interest of decision-makers across the industry. But, as the space continues to mature, conversations are shifting from what the technology can do, to how companies can use it most effectively and appropriately. At the Reuters Pharma Europe conference in Barcelona in April, Deep Dive editor Eloise McLennan spoke with Florian Schnappauf, VP of Commercial Strategy for Veeva AI in Europe, to learn more about what it means to be AI-ready in 2026.
Open in Who Shared Issue with article?
See all 213 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified